Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

Related Articles by Review for PubMed (Select 18310190)

1.

Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues.

Bailey DB Jr, Skinner D, Davis AM, Whitmarsh I, Powell C.

Pediatrics. 2008 Mar;121(3):e693-704. doi: 10.1542/peds.2007-0820. Review.

2.

Newborn screening for fragile X syndrome.

Bailey DB Jr.

Ment Retard Dev Disabil Res Rev. 2004;10(1):3-10. Review.

PMID:
14994282
3.

Newborn screening for fragile X syndrome.

Tassone F.

JAMA Neurol. 2014 Mar;71(3):355-9. doi: 10.1001/jamaneurol.2013.4808. Review.

4.

Screening for fragile X syndrome.

Murray J, Cuckle H, Taylor G, Hewison J.

Health Technol Assess. 1997;1(4):i-iv, 1-71. Review.

5.

Cystic fibrosis and fragile X syndrome: the arguments for antenatal screening.

Murray J, Cuckle H.

Comb Chem High Throughput Screen. 2001 May;4(3):265-72. Review.

PMID:
11375741
6.

Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review.

Green JM, Hewison J, Bekker HL, Bryant LD, Cuckle HS.

Health Technol Assess. 2004 Aug;8(33):iii, ix-x, 1-109. Review.

7.
8.

The genetic testing of children for cancer susceptibility: ethical, legal, and social issues.

Patenaude AF.

Behav Sci Law. 1996 Autumn;14(4):393-410. Review.

PMID:
9156420
9.

A systematic review of population screening for fragile X syndrome.

Hill MK, Archibald AD, Cohen J, Metcalfe SA.

Genet Med. 2010 Jul;12(7):396-410. doi: 10.1097/GIM.0b013e3181e38fb6. Review.

PMID:
20548240
10.

Disclosing to parents newborn carrier status identified by routine blood spot screening.

Oliver S, Dezateux C, Kavanagh J, Lempert T, Stewart R.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003859. Review.

PMID:
15495068
11.

Neonatal screening: ethical aspects.

Hermerén G.

Acta Paediatr Suppl. 1999 Dec;88(432):99-103. Review.

PMID:
10626591
12.

Ethical problems with neonatal screening.

Orzalesi M, Danhaive O.

Ann Ist Super Sanita. 2009;45(3):325-30. Review.

13.

[Screening for fragile X syndrome. International experiences].

Vuust J, Larsen LA, Grønskov K, Nørgaard-Pedersen B, Brøndum-Nielsen K.

Ugeskr Laeger. 2006 Oct 23;168(43):3704-9. Review. Danish.

PMID:
17069733
14.

Ethical dimensions of genetics in pediatric neurology: a look into the future.

Avard DM, Knoppers BM.

Semin Pediatr Neurol. 2002 Mar;9(1):53-61. Review.

PMID:
11931127
15.

Confused legal and medical policy: the misconceptions of genetic screening.

Kegley JA.

Med Law. 2000;19(2):197-207. Review.

PMID:
10994210
16.

Navigating the maze of newborn screening.

Spahis JK, Bowers NR.

MCN Am J Matern Child Nurs. 2006 May-Jun;31(3):190-6. Review.

PMID:
16679962
17.

Fragile X syndrome.

Welch JL, Williams JK.

Neonatal Netw. 1999 Sep;18(6):15-22. Review.

PMID:
10690095
18.

Ethical, social and legal implications of genetic testing in liver disease.

van Leeuwen DJ, Bernat JL.

Hepatology. 2006 Jun;43(6):1195-201. Review.

PMID:
16729331
19.

Genetics in dental practice: social and ethical issues surrounding genetic testing.

Gettig E, Hart TC.

J Dent Educ. 2003 May;67(5):549-62. Review.

20.

Ethical issues concerning genetic testing and screening in public health.

Hodge JG Jr.

Am J Med Genet C Semin Med Genet. 2004 Feb 15;125C(1):66-70. Review.

PMID:
14755435
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk